Abstract:Abstract Cellular thymidine metabolism involves two pathways: the catabolic and salvage pathways. The catabolic pathway breaks down thymidine to carbon dioxide for energy while the salvage pathway converts thymidine to its 5′-triphosphate as one of building blocks for DNA synthesis. Cytosolic level of thymidine is regulated by both thymidine phosphorylase (TYMP) of the catabolic pathway and thymidine kinase (TK) of the salvage pathway. In tumor tissues and cancer cells, abnormally high levels of these two proteins have been consistently reported. Therefore, thymidine metabolic pathways in cancer cells are a potential therapeutic target for novel drug design and development. We recently developed a novel thymidine analog, 3′-deoxythymidine phenylquinoxaline conjugate (dT-QX) that selectively killed a series of cancer cell lines including human liver carcinoma HepG2 and Hep3B, breast adenocarcinoma MCF-7, rat brain glioma C6 and mouse liver cancer H22 cells and showed low cytotoxicity on the normal liver hepatocyte HL-7702 cells. dT-QX is a conjugate of 3′-deoxythymidine and a DNA intercalating moiety with a triazole linkage achieved by click chemistry. The selective killing of cancer cells was attributed to the selective inhibition of DNA synthesis in the cancer cells but not in normal liver HL-7702 cells, resulting in extensive production of mitochondrial superoxide stress. The conjugation of 3′-deoxythymidine was found to be critical for dT-QX to achieve the selective killing of cancer cells. The killing by dT-QX was revealed to be directly due to the expression levels of TYMP and TKs in cancer cells, confirming that dT-QX successfully targeted the thymidine metabolic pathways as designed. Finally, a preliminary mouse study with subcutaneous liver tumors confirmed that dT-QX effectively inhibited the growth of tumors in vivo. Citation Format: Qibing Zhou, Qiong Wei, Dejun Zhang. Targeting thymidine metabolic pathways in cancer cells with a novel thymidine conjugate. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5503. doi:10.1158/1538-7445.AM2013-5503

Structure–activity relationship study of anticancer thymidine–quinoxaline conjugates under the low radiance of long wavelength ultraviolet light for photodynamic therapy

Abstract 177: Thymidine Quinoxaline Conjugates As a Novel Selective and Effective Photosensitizer for Anticancer Photodynamic Therapy

Design, Synthesis, and in Vitro and in Vivo Biological Studies of a 3'-Deoxythymidine Conjugate That Potentially Kills Cancer Cells Selectively.

Anticancer Activity of a Thymidine Quinoxaline Conjugate is Modulated by Cytosolic Thymidine Pathways.

Abstract 5503: Targeting Thymidine Metabolic Pathways in Cancer Cells with a Novel Thymidine Conjugate.

Design, Synthesis, Physicochemical Properties, and Biological Activity of Thymidine Compounds Attached to 5,8-Quinolinedione Derivatives as Potent DT-Diaphorase Substrates

X-Ray-Sensitizers: Organic Pharmaceutical Drug Intermediates Activated Directly by X-Rays to Efficiently Populate Triplet Excitons for Cancer Treatment

Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.

Slight Modification of a G-quadruplex-targeted Quinoxaline May Boost Type-1 Photodynamic Therapy for Triple-Negative Breast Cancer

Ultra-high photoactive thiadiazolo[3,4-<i>g</i>]quinoxaline nanoparticles with active-targeting capability for deep photodynamic therapy

In Situ Spectroeletrochemistry and Cytotoxic Activities of Natural Ubiquinone Analogues

Abstract 2736: Thymidine Catabolic and Salvage Pathways Are Responsible for the Heterogeneity of Anticancer Agent Dt-Qx in Liver Cancer Cells

A thermally activated delayed fluorescence photosensitizer for photodynamic therapy of oral squamous cell carcinoma under low laser intensity

Design, Synthesis, Structure-Activity Relationships and Mechanism of Action of New Quinoline Derivatives As Potential Antitumor Agents

Potent Cytotoxicity of Novel L-Shaped Ortho-Quinone Analogs Through Inducing Apoptosis.

Ultra-high photoactive thiadiazolo[3,4- g ]quinoxaline nanoparticles with active-targeting capability for deep photodynamic therapy

Red-emissive Azabenzanthrone Derivatives for Photodynamic Therapy Irradiated with Ultralow Light Power Density and Two-Photon Imaging.

Design, synthesis, and evaluation of proliferation inhibitory activity of novel L-shaped ortho-quinone analogs as anticancer agents

Quinacridone Derivative As a New Photosensitizer: Photodynamic Effects in Cells and in Vivo

DNA-Targeting Bioactive Photosensitizer for Chemo-Photodynamic Therapy of Malignant Tumor

Dithiocarbazate–Zn(II) complexes for photodynamic therapy and chemotherapy against lung cancer